Uwell Biopharma, Inc. (TPEX:7902)
Taiwan
· Delayed Price · Currency is TWD 46.75
-0.20 (-0.43%)
At close: Apr 28, 2026
Uwell Biopharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Net Income | -54.86 | -40.87 | -45.17 | -41.47 | -49.99 | -39.45 | Upgrade
|
| Depreciation & Amortization | 7.91 | 7.51 | 7.24 | 7.18 | 6.36 | 4.17 | Upgrade
|
| Stock-Based Compensation | 0.54 | - | - | - | - | - | Upgrade
|
| Other Operating Activities | -0.02 | 0.03 | -0.06 | - | - | -0.03 | Upgrade
|
| Change in Accounts Receivable | - | - | - | 0.02 | 0.78 | -0.75 | Upgrade
|
| Change in Accounts Payable | 7.22 | 1.53 | -1.51 | -0.1 | 1.69 | 1.29 | Upgrade
|
| Change in Other Net Operating Assets | -0.71 | -0.57 | -1.13 | -0.88 | -1.48 | -0.34 | Upgrade
|
| Operating Cash Flow | -39.91 | -32.38 | -40.63 | -35.24 | -42.64 | -35.1 | Upgrade
|
| Capital Expenditures | -0.47 | - | -2.01 | -0.62 | -1 | -19.08 | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | - | - | -0.2 | -0.47 | Upgrade
|
| Investment in Securities | 40.5 | 58.5 | -63 | 18 | -18 | - | Upgrade
|
| Other Investing Activities | -1.26 | -1.26 | 0.21 | - | - | -0.57 | Upgrade
|
| Investing Cash Flow | 38.77 | 57.24 | -64.8 | 17.38 | -19.21 | -20.11 | Upgrade
|
| Long-Term Debt Repaid | - | -4.55 | -4.2 | -4.19 | -4.07 | -3.64 | Upgrade
|
| Net Debt Issued (Repaid) | -5.04 | -4.55 | -4.2 | -4.19 | -4.07 | -3.64 | Upgrade
|
| Issuance of Common Stock | 200 | - | 105 | - | 80 | - | Upgrade
|
| Financing Cash Flow | 194.97 | -4.55 | 100.81 | -4.19 | 75.93 | -3.64 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.02 | - | 0.01 | -0 | -0.01 | 0.01 | Upgrade
|
| Net Cash Flow | 193.8 | 20.3 | -4.62 | -22.05 | 14.07 | -58.85 | Upgrade
|
| Free Cash Flow | -40.38 | -32.38 | -42.64 | -35.86 | -43.65 | -54.18 | Upgrade
|
| Free Cash Flow Margin | -8972.67% | -7196.22% | - | - | - | - | Upgrade
|
| Free Cash Flow Per Share | -0.34 | -0.28 | -0.48 | -0.63 | -1.85 | -2.56 | Upgrade
|
| Cash Interest Paid | 0.17 | 0.21 | 0.22 | 0.28 | 0.42 | 0.34 | Upgrade
|
| Cash Income Tax Paid | 0.02 | 0.01 | - | - | - | - | Upgrade
|
| Levered Free Cash Flow | - | -17.99 | -26.88 | -21.43 | -25.87 | -39.29 | Upgrade
|
| Unlevered Free Cash Flow | - | -17.86 | -26.74 | -21.26 | -25.61 | -39.07 | Upgrade
|
| Change in Working Capital | 6.51 | 0.96 | -2.64 | -0.95 | 0.99 | 0.21 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.